Atriva Therapeutics GmbH news

• Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board
• The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including Omicron

Atriva Therapeutics GmbH, a biopha

• Prof. Oliver Planz to step down as CSO at Atriva by mid-year 2022
• Prof. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today that Prof. Dr. Oliver Planz will not extend his contract as Chief Scientific Officer (CSO) beyond June 30, 2022. The Atriva co-foun

• FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases
• ODD allows Atriva to benefit from various incentives to develop zapnometinib (ATR-002) against hantavirus infections, and may result in seven-year market exclusivity on approval for this indication
• Targeting RNA viruses like hantavirus and acting in the host cell, oral drug c